We are live on
!
Find out more
Regeneron Pharmaceuticals
REGN
REGN
371 hedge funds and large institutions have $17B invested in Regeneron Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 371 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
14% more call options, than puts
Call options by funds: $300M | Put options by funds: $263M
Holders
371
Holders Change
+371
Holders Change %
–
% of All Funds
12.11%
Holding in Top 10
9
Holding in Top 10 Change
+9
Holding in Top 10 Change %
% of All Funds
0.29%
New
371
Increased
–
Reduced
–
Closed
–
Calls
$300M
Puts
$263M
Net Calls
+$37.1M
Net Calls Change
+$37.1M
Top Buyers
No buyers this quarter
Top Sellers
No sellers this quarter
REGN Hedge Fund Activity: Q2 2013 in Review
371 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2013, worth a combined $17B.
Buyers outnumbered sellers: 371 funds opened new REGN positions and 0 closed out — a net gain of 371 holders — while 0 added to existing stakes and 0 trimmed.
- 371 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2013, up from 0 in Q1 2013.
- Funds reported $17B of Regeneron Pharmaceuticals stock for Q2 2013.
- 371 funds opened new Regeneron Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +371 holders.
Based on aggregated 13F filings for Q2 2013.